Chemotherapy-Induced Neutropenia Treatment Market Growth, Size, Trends Analysis - By Treatment Type, By Drug Type, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Chemotherapy-Induced Neutropenia Treatment Market Introduction and Overview

According to SPER Market Research, 'Global Chemotherapy-Induced Neutropenia Treatment Market Growth, Size, Trends Analysis - By Treatment Type, By Drug Type, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Chemotherapy-Induced Neutropenia Treatment Market is predicted to reach 895.55 million by 2034 with a CAGR of 3.96%.

Chemotherapy-induced neutropenia (CIN) frequently occurs as a side effect of chemotherapy. Neutropenia is characterized by a reduction in the number of neutrophils, a variety of white blood cells essential for combating infections. The administration of chemotherapy drugs inhibits the bone marrow's capacity to generate neutrophils, resulting in a weakened immune response and heightened vulnerability to infections. As a consequence, CIN may lead to delays or reductions in chemotherapy doses, thus affecting the overall effectiveness of the treatment.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Treatment Type, By Drug Type, By Route of Administration, By Distribution Channel

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered Amgen Inc, BeyondSpring Inc, Biocon Biologics Inc, Cellerant Therapeutics, Coherus BioSciences, Inc, Evive Biotech, Kyowa Kirin Co., Ltd, Novartis AG, Pfizer Inc, Sanofi.

Global Chemotherapy-Induced Neutropenia Treatment Market Segmentation:

By Treatment Type: Based on the Treatment Type, Global Chemotherapy-Induced Neutropenia Treatment Market is segmented as; Granulocyte colony-stimulating factor therapy, Antibiotics, Granulocyte transfusion, Antifungals, Other treatment type.

By Drug Type: Based on the Drug Type, Global Chemotherapy-Induced Neutropenia Treatment Market is segmented as; Branded, Biosimilars.

By Route of administration: Based on the Route of administration, Global Chemotherapy-Induced Neutropenia Treatment Market is segmented as; Parenteral, Oral.

By Distribution Channel: Based on the Distribution Channel, Global Chemotherapy-Induced Neutropenia Treatment Market is segmented as; Hospital pharmacies, Retail pharmacies, Online pharmacies.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA25303

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Chemotherapy-Induced Neutropenia Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Chemotherapy-Induced Neutropenia Treatment Market

7. Global Chemotherapy-Induced Neutropenia Treatment Market, By Treatment Type (USD Million) 2021-2034

7.1. Granulocyte colony-stimulating factor therapy
7.2. Antibiotics
7.3. Granulocyte transfusion
7.4. Antifungals
7.5. Other treatment type

8. Global Chemotherapy-Induced Neutropenia Treatment Market, By Drug Type (USD Million) 2021-2034

8.1. Branded
8.2. Biosimilars

9. Global Chemotherapy-Induced Neutropenia Treatment Market, By Route of Administration (USD Million) 2021-2034

9.1. Parenteral
9.2. Oral

10. Global Chemotherapy-Induced Neutropenia Treatment Market, By Distribution Channel (USD Million) 2021-2034

10.1. Hospital pharmacies
10.2. Retail pharmacies
10.3. Online pharmacies

11. Global Chemotherapy-Induced Neutropenia Treatment Market, (USD Million) 2021-2034

13.1. Global Chemotherapy-Induced Neutropenia Treatment Market Size and Market Share

12. Global Chemotherapy-Induced Neutropenia Treatment Market, By Region, (USD Million) 2021-2034

12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America

13. Company Profile

13.1. Amgen Inc
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. BeyondSpring Inc
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Biocon Biologics Inc
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. Cellerant Therapeutics
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. Coherus BioSciences, Inc
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. Evive Biotech
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. Kyowa Kirin Co., Ltd
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Novartis AG
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. Pfizer Inc
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. Sanofi
- 15.10.1. Company details
- 15.10.2. Financial outlook
- 15.10.3 Product summary
- 15.10.4. Recent developments
13.11. Others